Cobra Biologics has been granted a Commercial Licence from the UK Medicines and Healthcare products Regulatory Agency (MHRA), to manufacture and distribute a product for commercial supply.
The MHRA Commercial Licence adds to Cobra’s existing licence for Investigational Medicinal Product (IMP) manufacture, which Cobra has held for over 15 years having continuous compliance for production of products for use in clinical trials. The issuing of a licence for commercial supply of the product is a significant step towards Cobra holding an unrestricted license for its DNA and viral vector services in its current and expanded manufacturing facilities.
Peter Coleman, Chief Executive at Cobra Biologics, commented: “The Cobra team at Keele has worked extremely hard in difficult circumstances to obtain a commercial licence from the MHRA. This is a tremendous achievement for Cobra."